The Opticyte VitalO₂ is a $3 Billion+ Global Market Opportunity

Opticyte has been capital-efficient and funded with non-dilutive grants and angel investments. The company has issued patents, a clear FDA De Novo pathway and Breakthrough Device Designation, and the potential to deliver significant cost savings to hospitals. Demonstrating strong momentum and credibility, Opticyte is a medical device innovator to watch.

“I am confident that should the preliminary data be confirmed in larger studies, there will be rapid and widespread adoption of this technology in both the hospital and prehospital settings.”
Eileen M. Bulger, MD, Chief of Trauma, Harborview Medical Center, Seattle

Connect with the Opticyte Team

If you’re a qualified investor and potential partner interested in Opticyte’s preclinical stage technology please reach out through our contact form.

Connect